Literature DB >> 10211132

A glutamatergic deficiency model of schizophrenia.

A Carlsson1, L O Hansson, N Waters, M L Carlsson.   

Abstract

Although the presence of hyperdopaminergia has been demonstrated in the brains of people with schizophrenia, at least in some circumstances, other neurotransmitters are important in this disorder, and a glutamatergic deficiency model of schizophrenia is proposed. It is suggested that the amount of sensory input allowed to reach the cerebral cortex is restricted by an inhibitory effect of the striatal complexes on the thalamus, thereby protecting it from being overwhelmed. Several strands of evidence are presented to support the concept that a weakened glutamatergic tone increases the risk of sensory overload and of exaggerated responses in the monoaminergic systems that could result in psychosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211132

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  25 in total

1.  Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.

Authors:  A R Owolabi; M A Akanmu; O E Ukponmwan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-12       Impact factor: 3.000

2.  A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades.

Authors:  Ilhame Ameqrane; Ameqrane Ilhame; Nicolas Wattiez; Wattiez Nicolas; Pierre Pouget; Pouget Pierre; Marcus Missal; Missal Marcus
Journal:  Psychopharmacology (Berl)       Date:  2015-07-09       Impact factor: 4.530

Review 3.  Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications.

Authors:  Johann Steiner; Kolja Schiltz; Hans-Gert Bernstein; Bernhard Bogerts
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 4.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 5.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 6.  Imaging the deluded brain.

Authors:  Astrid Knobel; Andreas Heinz; Martin Voss
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

7.  Postnatal exposure to MK801 induces selective changes in GAD67 or parvalbumin.

Authors:  Christopher Paul Turner; Danielle DeBenedetto; Emily Ware; Robert Stowe; Andrew Lee; John Swanson; Caroline Walburg; Alexandra Lambert; Melissa Lyle; Priyanka Desai; Chun Liu
Journal:  Exp Brain Res       Date:  2009-11-03       Impact factor: 1.972

8.  Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study.

Authors:  R A E Honey; G D Honey; C O'Loughlin; S R Sharar; D Kumaran; E T Bullmore; D K Menon; T Donovan; V C Lupson; R Bisbrown-Chippendale; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

9.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

10.  Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration.

Authors:  Wendy H Fasulo; Scott E Hemby
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.